RxDoctor Payments Data

Moira Haren, PA

Physician Assistant · Cincinnati, OHNPI 1740345032

Payments from drug & device makers

$1,010in general payments, 2019–2025

Across 47 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$160
  • Takeda Pharmaceuticals U.S.A., Inc.$155
  • Amgen$118
  • Lilly USA, LLC$90
  • Eisai Inc.$74
  • Merck$72
  • plus $342 from 13 others

What the payments were for

  • Food & beverage$1,010100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,010 in reported general payments places this provider in the 75th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$45,283
Medicare patients
175
Services billed
815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide57$31,819
EliquisApixaban24$20,558
MyrbetriqMirabegron29$14,866
XareltoRivaroxaban15$12,373
BelsomraSuvorexant17$7,145
Ziprasidone Hcl12$2,713
Risperidone147$2,063
Rivastigmine12$1,872
Divalproex Sodium74$1,814
Duloxetine Hcl87$1,709
Quetiapine Fumarate126$1,644
Dantrolene Sodium13$1,481
Escitalopram Oxalate159$1,463
Clonazepam98$1,387
Donepezil Hcl115$1,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$155$31,81957 claims
PfizerEliquis$13$20,55824 claims
MerckBelsomra$72$7,14517 claims
Lilly USA, LLCOlanzapine$90$88653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →